Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07349134

WELL-MPN: A Digital Lifestyle App for Patients With MPNs

Conditions: Myeloproliferative Neoplasms (MPNs)

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 75
Sponsor: Brigham and Women's Hospital

Location: Mass General Brigham Boston Massachusetts

Summary

The goal of this clinical trial is to learn whether a digital lifestyle app can help improve diet, physical activity, symptoms, emotional well-being, and quality of life in adults with myeloproliferative neoplasms (MPNs). The main questions it aims to answer are: Can people with MPNs use the WELL-MPN app? Does using the WELL-MPN app improve diet quality and physical activity? Does the WELL-MPN app improve MPN-related symptoms, anxiety and depression, confidence in managing health, and overall quality of life? Researchers will compare participants who use the WELL-MPN digital app with participants who receive written educational materials about diet and physical activity for people with cancer to see if the app leads to greater improvements in lifestyle behaviors, symptoms, and well-being. Participants will: Be randomly assigned to use the WELL-MPN app or receive written lifestyle education materials Use the assigned program or materials over the study period Complete surveys about diet, physical activity, symptoms, mood, confidence in self-care, and quality of life

Eligibility Criteria

Inclusion Criteria: * Diagnosed with a myeloproliferative neoplasm (MPN) by World Health Organization 2016 criteria * Adult (age \>/= 18) * Able to comprehend and speak English * Able to provide informed consent Exclusion Criteria: * Unable to comprehend and speak English * Unable to provide informed consent

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07349134). StuddyBuddy aggregates publicly available trial information.